Platinum IV Complex TU-31 Lipophilicity and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current platinum (II) complexes used in cancer therapy face challenges such as toxicity, stability issues, and resistance in tumors, limiting their efficacy and requiring improvement in cellular penetration and stability.
Innovation Solution
A platinum (IV) complex with a 'cis-trans-cis' configuration, specifically TU-31, featuring multiple 1-adamantyl groups for enhanced lipophilicity and stability, is developed, allowing better penetration through cell membranes and improved therapeutic index, along with a process for its preparation using 1-adamantylcarbonyl chloride and pyridine in a non-polar aprotic solvent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If platinum (II) complexes are used for cancer therapy, then direct DNA cross-linking and cell killing efficacy are achieved, but toxicity to healthy cells and stability issues occur
Solution Approach 1:
The patent changes the oxidation state parameter of platinum from (II) to (IV), which fundamentally alters the chemical properties. Pt(IV) complexes exhibit improved stability and reduced toxicity compared to Pt(II) complexes, while maintaining DNA cross-linking capability. This parameter change resolves the contradiction by allowing the drug to remain stable in circulation and less toxic to healthy cells, while still achieving effective DNA damage in tumor cells.
Solution Approach 2:
The patent introduces additional ligands to create Pt(IV) complexes with specific configurations (cis-trans-cis geometry). These composite structures include multiple ligands (A1, A2, B1, B2, C1, C2) that work together to provide both stability in circulation and controlled reactivity at the target site, resolving the contradiction between efficacy and toxicity.
2Reliability
If platinum (II) complexes are administered, then DNA cross-linking occurs in cancer cells, but reactivity and stability after administration are poor
Solution Approach 1:
The patent changes the oxidation state from +2 to +4, which increases the kinetic stability of the complex. Pt(IV) complexes are more stable in physiological conditions and less prone to premature decomposition, while still maintaining the ability to form DNA cross-links through hydrolysis of leaving groups at the target site.
Solution Approach 2:
The Pt(IV) complex is designed with leaving groups (C1 and C2) that are stable during circulation but undergo hydrolysis at the target site to generate the active DNA-crosslinking species. This preliminary configuration allows the drug to remain stable during administration while ensuring DNA cross-linking capability is activated at the right location and time.
3Ease of operation
If platinum (IV) complexes with increased lipophilicity are developed, then cell membrane penetration is improved, but selectivity between tumor and healthy cells may be reduced
Solution Approach 1:
The patent optimizes the lipophilicity parameter by selecting specific ligands (A1, A2 as aminoligands and B1, B2 as carboxylate ligands) that provide appropriate membrane penetration capability. The cis-trans-cis configuration with these specific ligands achieves a balance between lipophilicity for membrane crossing and hydrophilicity for selective accumulation in tumor tissue, resolving the contradiction between penetration and selectivity.
Data Source
AI summary
The invention relates to a new platinum (IV) complex with substantially increased antitumor efficacy. The invention further discloses a process for preparing of said complex and a pharmaceutical composition for the therapy of tumor diseases containing said complex.